Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reduced NCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”

Letai: Perceptions aside, money is flowing and the cancer research infrastructure is sturdy
NCI expects record-breaking spending on extramural research

Over the course of his first six months as NCI director, Anthony Letai has contended with federal budget turbulence, a record-setting government shutdown, and concerns about the flow of over research dollars.

April 10, 2026

Vol.52 No.14

By Claire Marie Porter and Paul Goldberg

Cancer Policy

President’s budget request would cap indirect costs and fully fund all NIH research projects upfront

NCI has emerged relatively unscathed in the president’s FY 2027 budget request that would slash $15.8 billion from HHS funding, cut NIH overall by about 10%, eliminate three NIH institutes and centers, and move the Institute for Environmental Health Sciences and its circa $1 billion budget out of NIH.

April 10, 2026

Vol.52 No.14

By Claire Marie Porter and Jacquelyn Cobb

Podcast The Directors

The Directors: Wistar’s Altieri and ChristianaCare’s Petrelli say partnership of their institutions will go on as the guard changes

Leadership is changing at The Wistar Institute and the Helen F. Graham Cancer Center & Research Institute in the months to come—but the leaders of the two institutions say that this will have little if any effect on the clinical-research collaboration that they have spent the past 15years building (The Cancer Letter, July 12, 2019).

March 27, 2026

Vol.52 No.12

By Sara Willa Ernst and Paul Goldberg

Podcast

At a jam-packed NCAB meeting, cancer vaccines and site visits take center stage

Last week’s issue of The Cancer Letter was dominated by one event: the meeting of the National Cancer Advisory Board, the group of experts which advises and assists the NCI director on the activities of the National Cancer Program.

March 25, 2026

NCI

Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccines
NCI Director Letai: “How aggressive can we be?”

A public-private effort, spearheaded by NCI Director Anthony Letai, and led by the Foundation for the National Institutes of Health, is working to speed up the development of therapeutic cancer vaccines.

March 20, 2026

Vol.52 No.11

By Claire Marie Porter

NCI

Letai: “From this point forward, it really is much more like business as usual at the NCI.”

NCI Director Anthony Letai appeared before the National Cancer Advisory Board Committee March 17 to maneuver through thorny topics while reiterating his message of reassurance: Stability. Stability. Stability.

March 20, 2026

Vol.52 No.11

By Jacquelyn Cobb

Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reduced

NCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”

YOU MAY BE INTERESTED IN

Letai: Perceptions aside, money is flowing and the cancer research infrastructure is sturdy
NCI expects record-breaking spending on extramural research

President’s budget request would cap indirect costs and fully fund all NIH research projects upfront

The Directors: Wistar’s Altieri and ChristianaCare’s Petrelli say partnership of their institutions will go on as the guard changes

At a jam-packed NCAB meeting, cancer vaccines and site visits take center stage

Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccines
NCI Director Letai: “How aggressive can we be?”

Letai: “From this point forward, it really is much more like business as usual at the NCI.”

Renew today!

Subscriber content

Never miss an issue!

Login

Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reduced

NCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”

YOU MAY BE INTERESTED IN

Letai: Perceptions aside, money is flowing and the cancer research infrastructure is sturdyNCI expects record-breaking spending on extramural research

President’s budget request would cap indirect costs and fully fund all NIH research projects upfront

The Directors: Wistar’s Altieri and ChristianaCare’s Petrelli say partnership of their institutions will go on as the guard changes

At a jam-packed NCAB meeting, cancer vaccines and site visits take center stage

Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccinesNCI Director Letai: “How aggressive can we be?”

Letai: “From this point forward, it really is much more like business as usual at the NCI.”

Never miss an issue!

Login

Letai: Perceptions aside, money is flowing and the cancer research infrastructure is sturdy
NCI expects record-breaking spending on extramural research

Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccines
NCI Director Letai: “How aggressive can we be?”